Comparison between molecular epidemiology, geographical regions and drug resistance in Mycobacterium tuberculosis strains isolated from Iranian and Afghan patients.
The aim of this study was to determine the prevalence of drug-resistant tuberculosis (TB) and its associated risk factors. The susceptibilities of Mycobacterium tuberculosis isolates were tested against four first-line antituberculous drugs and were typed by spoligotyping. Spoligotyping of M. tuberculosis strains resulted in 95 different patterns that were divided into three evolutionary groups (1-3). Eighty-six (90%) of the isolates had unique patterns that were reported for the first time. Interestingly, 9.4% of the strains belonged to the Beijing family. Multidrug resistance (MDR) was seen in group 1 of the evolutionary scenario. All M. tuberculosis isolates belonging to the Beijing family were associated with a resistance pattern. MDR was much higher in bacteria isolated from Afghan TB patients residing in Iran.
Ramazanzadeh
Rashid
R
National Research Institute of Tuberculosis and Lung Disease, Shaheed Beheshti University of Medical Sciences, Tehran, Iran. atrop_t@yahoo.com
Farnia
Parissa
P
Amirmozafari
Nour
N
Ghazi
Farideh
F
Ghadertotonchi
Zeinab
Z
Kamran
Jaber
J
Mohammadi
Frouzan
F
Mirsaedi
Mehdi
M
Masjedi
Mohammadreza
M
D000328:Adult; D000346:Afghanistan / Q000453:epidemiology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects* / Q000235:genetics; D004977:Ethambutol / Q000627:therapeutic use; D005838:Genotype; D006801:Humans; D007492:Iran / Q000453:epidemiology; D007538:Isoniazid / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D017720:Molecular Epidemiology; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification*; D015995:Prevalence; D012293:Rifampin / Q000627:therapeutic use; D012307:Risk Factors; D013307:Streptomycin / Q000627:therapeutic use; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology* / Q000235:genetics / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin